MA53482B1 - Thérapie d'infections par le papillomavirus humain à haut risque - Google Patents

Thérapie d'infections par le papillomavirus humain à haut risque

Info

Publication number
MA53482B1
MA53482B1 MA53482A MA53482A MA53482B1 MA 53482 B1 MA53482 B1 MA 53482B1 MA 53482 A MA53482 A MA 53482A MA 53482 A MA53482 A MA 53482A MA 53482 B1 MA53482 B1 MA 53482B1
Authority
MA
Morocco
Prior art keywords
acid
human papillomavirus
therapy
following
composition
Prior art date
Application number
MA53482A
Other languages
English (en)
French (fr)
Other versions
MA53482A (fr
Inventor
Norbert Fuchs
Original Assignee
Selo Medical Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selo Medical Gmbh filed Critical Selo Medical Gmbh
Publication of MA53482A publication Critical patent/MA53482A/fr
Publication of MA53482B1 publication Critical patent/MA53482B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA53482A 2018-08-28 2019-08-28 Thérapie d'infections par le papillomavirus humain à haut risque MA53482B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18191289.0A EP3616693A1 (en) 2018-08-28 2018-08-28 Therapy of high-risk human papillomavirus infections
PCT/EP2019/072926 WO2020043762A1 (en) 2018-08-28 2019-08-28 Therapy of high-risk human papillomavirus infections

Publications (2)

Publication Number Publication Date
MA53482A MA53482A (fr) 2021-07-07
MA53482B1 true MA53482B1 (fr) 2023-11-30

Family

ID=63442535

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53482A MA53482B1 (fr) 2018-08-28 2019-08-28 Thérapie d'infections par le papillomavirus humain à haut risque

Country Status (25)

Country Link
US (2) US20210299163A1 (https=)
EP (2) EP3616693A1 (https=)
JP (1) JP7420791B2 (https=)
CN (1) CN112584828A (https=)
AR (1) AR116027A1 (https=)
AU (1) AU2019332079B2 (https=)
BR (1) BR112021003360A2 (https=)
CA (1) CA3107691C (https=)
CL (1) CL2021000197A1 (https=)
EA (1) EA202190441A1 (https=)
ES (1) ES2958808T3 (https=)
GE (2) GEAP202215586A (https=)
HR (1) HRP20231470T1 (https=)
HU (1) HUE064691T2 (https=)
IL (1) IL281080B2 (https=)
MA (1) MA53482B1 (https=)
MD (1) MD3843715T2 (https=)
MX (1) MX2021002310A (https=)
PL (1) PL3843715T3 (https=)
RS (1) RS64916B1 (https=)
SM (1) SMT202300340T1 (https=)
TW (1) TWI827652B (https=)
UA (1) UA127632C2 (https=)
WO (1) WO2020043762A1 (https=)
ZA (1) ZA202100375B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3875083A1 (en) * 2020-03-03 2021-09-08 Selo Medical GmbH Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245301C2 (ru) 2000-05-10 2005-01-27 Окофарм Форшунгс-Унд Энтвиклюнгс-Гмбх Способ уменьшения площади поверхности диоксида кремния
AT412758B (de) 2000-06-05 2005-07-25 Vis Vitalis Lizenz & Handels Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
AT412448B (de) 2001-02-13 2005-03-25 Vis Vitalis Lizenz & Handels Verwendung von selenhältigen präparaten
AT412703B (de) * 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
AT511159A1 (de) * 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen

Also Published As

Publication number Publication date
CN112584828A (zh) 2021-03-30
CA3107691A1 (en) 2020-03-05
JP7420791B2 (ja) 2024-01-23
JP2021536454A (ja) 2021-12-27
GEP20227432B (en) 2022-10-25
EA202190441A1 (ru) 2021-06-15
MD3843715T2 (ro) 2023-12-31
AU2019332079B2 (en) 2024-08-29
CA3107691C (en) 2024-10-29
EP3616693A1 (en) 2020-03-04
RS64916B1 (sr) 2023-12-29
IL281080A (en) 2021-04-29
EP3843715A1 (en) 2021-07-07
WO2020043762A1 (en) 2020-03-05
IL281080B1 (en) 2024-08-01
HUE064691T2 (hu) 2024-04-28
US20250281524A1 (en) 2025-09-11
ZA202100375B (en) 2024-08-28
TWI827652B (zh) 2024-01-01
AR116027A1 (es) 2021-03-25
BR112021003360A2 (pt) 2021-05-11
EP3843715B1 (en) 2023-09-13
PL3843715T3 (pl) 2024-02-19
UA127632C2 (uk) 2023-11-08
MA53482A (fr) 2021-07-07
ES2958808T3 (es) 2024-02-15
MX2021002310A (es) 2021-04-28
IL281080B2 (en) 2024-12-01
US20210299163A1 (en) 2021-09-30
HRP20231470T1 (hr) 2024-03-01
SMT202300340T1 (it) 2023-11-13
EP3843715C0 (en) 2023-09-13
TW202023534A (zh) 2020-07-01
CL2021000197A1 (es) 2021-09-20
AU2019332079A1 (en) 2021-02-11
GEAP202215586A (en) 2022-06-27

Similar Documents

Publication Publication Date Title
JP2023002662A5 (https=)
M Tebit et al. Mucosal transmission of human immunodeficiency virus
WO1995003056A1 (en) Hepatitis c virus proliferation inhibitor
WO2018067217A3 (en) COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF
JP2019529541A5 (https=)
CN102274174B (zh) 苯并咪唑类药物油混悬剂
MA53482B1 (fr) Thérapie d'infections par le papillomavirus humain à haut risque
Gevorgyan et al. A nodular-ulcerative form of secondary syphilis in AIDS
CN114053475A (zh) 一种抗hpv医用妇科敷料
JP2021536454A5 (https=)
WO2017038872A1 (ja) 抗真菌活性を有する組成物
US20230285441A1 (en) Treatment of coronavirus infections with auranofin
WO2012097634A1 (zh) 一种治疗hpv感染的药物以及该药物在制备治疗hpv感染药物中的应用
MA58262B1 (fr) Composition destinée à être utilisée dans un traitement d'anomalies de cellules cervicales contenant un composé de sélénite et d'acide
JP2021521227A5 (https=)
JPWO2019224779A5 (https=)
US20070098687A1 (en) Pharmaceutical composition containing interferon for the treatment of hpv infections
Ganjoo et al. Isolated oral “snail track ulcers” as a manifestation of secondary syphilis
Narayana et al. Pathology of Infection and Infectious Diseases of the Oro‐Facial Complex
RU2025131205A (ru) Производные имидазотриазина в качестве модуляторов il-17
RU2480202C1 (ru) Способ реабилитации после деструктивных методов терапии при заболеваниях шейки матки, ассоциированных с папилломавирусной инфекцией
Jiang et al. Acquired Immune Deficiency Syndrome
EP4046646A1 (en) Pharmaceutical composition for the treatment of hpv infections
WO2023040990A1 (zh) 治疗冠状病毒感染的新联用药物、药物组合物及其用途
WO2012007658A4 (fr) Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives